Table 2.
Univariate and multivariate Cox proportional hazards regression analysis for DFS prediction in patients with NSCLC
| All NSCLC group | DFS | |||
| Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | P value | Relative risk (95% CI) | P value | |
| Age (years): ≥65 vs <65 | 1.417 (0.91 to 2.2) | 0.122 | – | – |
| Gender: male versus female | 1.322 (0.83 to 2.1) | 0.244 | – | – |
| Smoking history: smoker versus non-smoker | 1.323 (0.85 to 2.1) | 0.221 | – | – |
| Histology: LUAD versus LUSC | 1.218 (0.78 to 1.9) | 0.389 | – | – |
| Stage: III vs I | 1.756 (1.4 to 2.2) | <0.0001 | 1.65 (1.29 to 2.12) | <0.0001 |
| PD-L1: PD-L1+ versus PD-L | 1.366 (0.82 to 2.3) | 0.228 | – | – |
| CD47: CD47pos versus CD47neg | 1.734 (1.1 to 2.7) | 0.017 | 1.63 (1.04 to 2.58) | 0.035 |
| M2 location: T&NT versus NT | 2.036 (1.3 to 3.2) | 0.002 | 1.41 (0.86 to 2.31) | 0.17 |
| Ratio of tumour M2/M1: high versus low | 1.888 (1.1 to 3.2) | 0.021 | 1.23 (0.69 to 2.21) | 0.48 |
| EGFR: mutation versus wild type | 1.486 (0.91 to 2.4) | 0.110 | – | – |
| TP53: mutation versus wild type | 0.9975 (0.63 to 1.6) | 0.992 | – | – |
| KRAS: mutation versus wild type | 1.665 (0.85 to 3.2) | 0.134 | – | – |
| ERBB2: mutation versus wild type | 0.7146 (0.31 to 1.6) | 0.430 | – | – |
CD47neg, CD47 negative; CD47pos, CD47 positive; DFS, disease-free survival; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NSCLC, non-small cell lung cancer; NT, non-tumour area; T&NT, tumour area and non-tumour area.